218 related articles for article (PubMed ID: 32838492)
1. [Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].
Wang Y; Yuan X; Xiong J; Hao Z; Peng X; Chen W; Cui L; Li H; Wang X; He X; Yang M; Liang C; Ma Y; Ding L; Mao L
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):719-729. PubMed ID: 32838492
[TBL] [Abstract][Full Text] [Related]
2. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yang Y; Zhou J; Zhou J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wu N; Song W; Liu X; Zhao S; Ding L; Mao L; Selvaggi G; Yuan X; Fu Y; Wang T; Xiao S; Zhang L
Lancet Respir Med; 2020 Jan; 8(1):45-53. PubMed ID: 31628085
[TBL] [Abstract][Full Text] [Related]
4. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
5. Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC.
Li T; Ma W; Tian EC
Chin Clin Oncol; 2019 Oct; 8(S1):S4. PubMed ID: 30525756
[No Abstract] [Full Text] [Related]
6. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Horn L; Infante JR; Reckamp KL; Blumenschein GR; Leal TA; Waqar SN; Gitlitz BJ; Sanborn RE; Whisenant JG; Du L; Neal JW; Gockerman JP; Dukart G; Harrow K; Liang C; Gibbons JJ; Holzhausen A; Lovly CM; Wakelee HA
Clin Cancer Res; 2018 Jun; 24(12):2771-2779. PubMed ID: 29563138
[No Abstract] [Full Text] [Related]
7. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
[TBL] [Abstract][Full Text] [Related]
8. Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Thorac Cancer; 2021 Sep; 12(17):2388-2399. PubMed ID: 34288491
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Horn L; Whisenant JG; Wakelee H; Reckamp KL; Qiao H; Leal TA; Du L; Hernandez J; Huang V; Blumenschein GR; Waqar SN; Patel SP; Nieva J; Oxnard GR; Sanborn RE; Shaffer T; Garg K; Holzhausen A; Harrow K; Liang C; Lim LP; Li M; Lovly CM
J Thorac Oncol; 2019 Nov; 14(11):1901-1911. PubMed ID: 31446141
[TBL] [Abstract][Full Text] [Related]
10. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
11. [Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer].
Zhang L; Yang YP; ;
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):297-307. PubMed ID: 35448917
[TBL] [Abstract][Full Text] [Related]
12. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
13. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
14. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
15. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Indini A; Rijavec E; Ghidini M; Bareggi C; Gambini D; Galassi B; Antonelli P; Bettio G; Di Nubila C; Grossi F
Expert Opin Pharmacother; 2020 Jun; 21(8):931-940. PubMed ID: 32162559
[TBL] [Abstract][Full Text] [Related]
17. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
18. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
19. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
20. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]